PharmaCell has entered into an agreement with Dendreon Corp. for the commercial manufacture of Dendreon’s recently approved cellular immunotherapy product Provenge dispersion for infusion. Provenge was granted marketing authorization in the EU for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer in adults where chemotherapy is not yet indicated. Provenge was approved in the U.S. in 2010 and is produced by Dendreon at its own manufacturing facilities. 
 
Alexander Vos, chief executive officer of PharmaCell B.V. said, “We are extremely pleased that an immunotherapy industry leader such as Dendreon has decided to continue its relationship with PharmaCell. We have worked with Dendreon since 2011, and the decision to extend our relationship is a testament to the dedication and expertise of our team who have worked with Dendreon throughout the Technology Transfer and European approval process over the past few years.”